Fig. 6: RNA editing analysis in ADAR-KO teratomas.
From: Charting and probing the activity of ADARs in human development and cell-fate specification
a Workflow schematic for ADAR-KO screen in PGP1-Cas9 iPSCs, followed by teratoma formation and downstream single cell RNA editing analysis. b Aggregated UMAP plot from 4 PGP1-Cas9 + ADAR-KO teratomas. c AEI values for all teratoma cell-types in ADAR-KO teratomas. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001; ns, not significant). d Pan-teratoma site-specific RNA editing analysis across KO conditions. Centerline of the box represents the mean, the box represents the 95% confidence interval, and the error bar is the standard error of the mean. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001; ns, not significant). n = 5166 ALU repeat sites, n = 84 non-ALU Repetitive Region sites, n = 338 non-Repetitive Region sites. ANOVA is used for comparing the mean and Tukey’s significance test is used to determine which mean differences are statistically significant.
